Medication usage and the risk of neoplasia in patients with Barrett's esophagus.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2009-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2009.06.001PMID 19523538PMCID PMC2789910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Statins Inhibit Proliferation and Induce Apoptosis in Barrett's Esophageal Adenocarcinoma Cells

  2008cited by this paper
• Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus

  2008cited by this paper
• Statins and cancer risk.

  2008cited by this paper
• Trial watch

  2007cited by this paper
• Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial.

  2007cited by this paper
• Barrett's Esophagus and Medications that Relax the Lower Esophageal Sphincter

  2006cited by this paper
• Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence

  2006cited by this paper
• Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.

  2005cited by this paper
• Proton Pump Inhibitors Are Associated with Reduced Incidence of Dysplasia in Barrett's Esophagus

  2004cited by this paper
• Daily use of non‐steroidal anti‐inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma

  2004cited by this paper
• Proton‐pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus

  2004cited by this paper
• Trends in Incidence and Prevalence of Specialized Intestinal Metaplasia, Barrett’s Esophagus, and Adenocarcinoma of the Gastroesophageal Junction

  2003cited by this paper
• Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.

  2003cited by this paper
• Trends in Incidence and Prevalence of Specialized Intestinal Metaplasia, Barrett’s Esophagus, and Adenocarcinoma of the Gastroesophageal Junction

  2003cited by this paper
• Cancer Research UK

  2002cited by this paper
• Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus.

  2002cited by this paper
• Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence

  2001cited by this paper
• 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.

  2000cited by this paper
• Barrett's oesophagus and proton pump inhibitors: a pathological perspective

  2000cited by this paper
• Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

  1999cited by this paper
• The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia.

  1995cited by this paper

• Chemoprevention in Barrett's Esophagus: An Updated Review.

  2025cites this paper
• The association between obesity and malignant progression of Barrett's Esophagus: a systematic review and dose-response meta-analysis.

  2024cites this paper
• Proton pump inhibitors and risk of gastrointestinal cancer: A meta‑analysis of cohort studies

  2023cites this paper
• Systematic Review and Meta-Analysis of the Relationship between Proton Pump Inhibitors and Esophageal Adenocarcinoma.

  2023cites this paper
• Molecular Biology and Clinical Management of Esophageal Adenocarcinoma

  2023cites this paper
• Revisiting Proton Pump Inhibitors as Chemoprophylaxis Against the Progression of Barrett’s Esophagus

  2023cites this paper
• Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis

  2023cites this paper
• Barrett’s esophagus: results from an Italian cohort with tight endoscopic surveillance

  2022cites this paper
• Quality in Barrett's Esophagus: Diagnosis and Management

  2022cites this paper
• Antireflux and Endoscopic Therapies for Barrett Esophagus and Superficial Esophageal Neoplasia.

  2021cites this paper
• Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis

  2021cites this paper
• Prevention Strategies for Esophageal Cancer—An Expert Review

  2021cites this paper
• Gastrointestinal diseases: Sex and gender evidence in liver lesions, gastroesophageal reflux, and inflammatory bowel disease

  2021cites this paper
• Gastrointestinal cancers in China, the USA, and Europe

  2021cites this paper
• Risk of esophageal adenocarcinoma in patients with Barrett’s esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis

  2021cites this paper
• Targeting the Microenvironment in Esophageal Cancer

  2021cites this paper
• Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett’s esophagus: a systematic review and meta-analysis

  2021cites this paper
• Barrett's esophagus surveillance in a prospective Dutch multi‐center community‐based cohort of 985 patients demonstrates low risk of neoplastic progression

  2021cites this paper
• Cancer Prevention in Patients with GERD and Barrett’s Esophagus—Medicine

  2021cites this paper
• 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease

  2021cites this paper
• Statins as Potential Therapeutics for Esophageal Cancer

  2021cites this paper
• Gastrointestinal pharmacology: practical tips for the esophagologist

  2020cites this paper
• Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus Using Proton Pump Inhibitors: A Systematic Review With Meta-Analysis and Trial Sequential Analysis

  2020cites this paper
• Low Risk of Progression of Barrett's Esophagus to Neoplasia in Women.

  2020cites this paper
• Chemoprevention of esophageal adenocarcinoma

  2020cites this paper
• The Clinician’s Guide to Proton-Pump Inhibitor Discontinuation

  2019cites this paper
• Evaluation and Management of Premalignant Conditions of the Esophagus

  2019cites this paper
• Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified

  2019cites this paper
• A review of the incidence of adenocarcinoma detected during surveillance for Barrett's esophagus.

  2019cites this paper
• Omeprazole prevents CDX2 and SOX9 expression by inhibiting hedgehog signaling in Barrett's esophagus cells.

  2019cites this paper
• A Systematic Review and Meta-Analysis of the Effect of Roux-en-Y Gastric Bypass on Barrett’s Esophagus

  2019cites this paper
• Barrett's esophagus: What do we need to know?

  2019cites this paper
• Medical and Surgical Therapy for Gastroesophageal Reflux Disease and Barrett Esophagus

  2019cites this paper
• The Role of Proton Pump Inhibitors in the Management of Upper Gastrointestinal Disorders.

  2018cites this paper
• Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case‐control study in US male veterans

  2018cites this paper
• Barrett's esophagus: A comprehensive review for the internist.

  2018cites this paper
• p53 protein accumulation predicts malignant progression in Barrett's metaplasia: a prospective study of 275 patients

  2017cites this paper
• Factors Associated With Progression of Barrett's Esophagus: A Systematic Review and Meta‐analysis

  2017cites this paper
• Oesophageal cancer

  2017cites this paper
• Aspirin Use is Associated With Lower Risk of Barrett’s Esophagus in Women

  2017cites this paper
• Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus: A Systematic Review and Meta-Analysis

  2017cites this paper
• Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors

  2017cites this paper
• andMeta-analysis : Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma

  2017influential citation
• Guías de diagnóstico , vigilancia y manejo del esófago de Barrett Asociación Mexicana de Endoscopia Gastrointestinal Diagnostic , surveillancee and management guidelines in Barrett ’ s Esophagus Asociación Mexicana de Endoscopia Gastrointestinal

  2017cites this paper
• Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma.

  2017cites this paper
• The potential role of statins in the treatment and prevention of oesophageal adenocarcinoma

  2017cites this paper
• Screening and Preventive Strategies in Esophagogastric Cancer.

  2017cites this paper
• ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus

  2016cites this paper
• Esophageal cancer: The latest on chemoprevention and state of the art therapies.

  2016cites this paper
• Metabolic syndrome, Barrett’s oesophagus, the risk of oesophageal adenocarcinoma, and statin treatment

  2016cites this paper
• Chemoprevention of Barrett’s Esophagus and Adenocarcinoma

  2016cites this paper
• Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus

  2016cites this paper
• Clinical Practice Guidelines on the Diagnosis and Treatment of Gastroesophageal Reflux Disease (GERD)

  2015cites this paper
• 52. Barrett Esophagus and Esophageal Adenocarcinoma

  2015cites this paper
• ESÓFAGO DE BARRETT: REVISIÓN DE LA LITERATURA

  2015cites this paper
• Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.

  2015cites this paper
• Clinical Guideline : Diagnosis and Management of Barrett ' s Esophagus

  2015cites this paper
• Medical Prevention of Barrett’s Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins

  2015cites this paper
• Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma

  2015cites this paper
• BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia

  2015cites this paper
• Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis.

  2015cites this paper
• Acid suppression and surgical therapy for Barrett's oesophagus.

  2015cites this paper
• Barrett's oesophagus: how should we manage it?

  2015cites this paper
• The Effect of Proton Pump Inhibitors on Barrett's Esophagus.

  2015cites this paper
• Esophageal cancer and barrett's esophagus: Sharma/Esophageal cancer and barrett's esophagus

  2015cites this paper
• Chemoprevention for Esophageal Carcinoma

  2015cites this paper
• Esophageal adenocarcinoma: Risk factors

  2015cites this paper
• Epidemiology of esophageal carcinoma

  2015cites this paper
• Aspirin and Proton Pump Inhibitor Combination Therapy for Prevention of Cardiovascular Disease and Barrett's Esophagus

  2014cites this paper
• XPD Asp312Asn polymorphism and esophageal cancer risk: an update meta-analysis based on 3928 cases and 6012 controls.

  2014cites this paper
• Esophageal carcinoma.

  2014cites this paper
• Statin use is associated with reduced risk of histologic subtypes of esophageal cancer: a nested case-control analysis.

  2014cites this paper
• Does Barrett's Esophagus Regress after Surgery (or Proton Pump Inhibitors)

  2014cites this paper
• Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.

  2014cites this paper
• Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis

  2014cites this paper
• Nonsteroidal Anti-inflammatory Drugs and Inflammatory Bowel Disease: Pathophysiology and Clinical Associations

  2014cites this paper
• Low grade dysplasia in Barrett's esophagus: Should we worry?

  2014cites this paper
• Risk factors for the development of oesophageal adenocarcinoma in Barrett’s oesophagus: a UK primary care retrospective nested case–control study

  2014cites this paper
• Letter: proton pump inhibitor usage still seems to reduce the risk of high‐grade dysplasia and/or oesophageal adenocarcinoma in Barrett's oesophagus – authors’ reply

  2014cites this paper
• Barrett’s Esophagus

  2014cites this paper
• Optimizing Surveillance in Barrett’s Esophagus: From Chemoprevention and Biomarkers to Cost-effectiveness and Survival

  2014cites this paper
• Esophageal Cancer: Current Diagnosis and

  2014cites this paper
• The esophagitis to adenocarcinoma sequence; the role of inflammation.

  2014cites this paper
• Proton pump inhibitor use may not prevent high‐grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients

  2014influential citation
• The non‐linear threshold association between aspirin use and esophageal adenocarcinoma: results of a dose–response meta‐analysis

  2014cites this paper
• The Dose of Omeprazole Required to Achieve Adequate Intraesophageal Acid Suppression in Patients with Gastroesophageal Junction Specialized Intestinal Metaplasia and Barrett’s Esophagus

  2013cites this paper
• Statin use and the risk of esophageal cancer: a population-based case-control study

  2013cites this paper
• Two-Year Subjective, Objective, Quality of Life, and Endoscopic Follow-up After Laparoscopic Nissen-Rossetti in Patients With Columnar-lined Esophagus

  2013cites this paper
• Chemoprevention of Gastrointestinal Neoplasia

  2013cites this paper
• Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis

  2013cites this paper
• Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.

  2013cites this paper
• British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus

  2013cites this paper
• Diagnosis and Management of Barrett’s Esophagus with and Without Dysplasia

  2013cites this paper
• Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus.

  2013cites this paper
• Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: a systematic review and meta-analysis

  2013cites this paper
• The spectrum of achalasia: lessons from studies of pathophysiology and high-resolution manometry.

  2013cites this paper
• Carcinogenesis of Barrett’s esophagus: a review of the clinical literature

  2013cites this paper
• Risk Factors in the Development of Esophageal Adenocarcinoma

  2013cites this paper
• Studies of the aetiology of oesophageal adenocarcinoma

  2013cites this paper
• Prevention of Barrett's metaplasia in a human model of duodenogastro-oesophageal reflux

  2013cites this paper